Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Summary

The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer in postmenopausal patients with locally advanced or metastatic breast cancer, and whether the side effects of the combination are different from the side effects of letrozole.

Timeline

Start

2002-06

Primary completion

2006-01

Completion

2006-01

Drugs

Indications